Get the Stockscreener App
5.13
5.00%
-0.27
After Hours:
5.10
-0.03
-0.58%
Unicycive Therapeutics Inc stock is traded at $5.13, with a volume of 631.48K.
It is down -5.00% in the last 24 hours and down -28.05% over the past month.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
See More
Previous Close:
$5.40
Open:
$5.36
24h Volume:
631.48K
Relative Volume:
0.45
Market Cap:
$140.53M
Revenue:
$675.00K
Net Income/Loss:
$-39.95M
P/E Ratio:
-2.4947
EPS:
-2.0564
Net Cash Flow:
$-28.67M
1W Performance:
-5.87%
1M Performance:
-28.05%
6M Performance:
-28.75%
1Y Performance:
+5.34%
1-Day Range:
$5.12
$5.50
1-Week Range:
$5.12
$5.87
52-Week Range:
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.13 | 147.92M | 675.00K | -39.95M | -28.67M | -2.0564 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive Therapeutics Inc (UNCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Unicycive Therapeutics, Inc. Revenue Breakdown – NASDAQ:UNCY - TradingView
Unicycive Therapeutics Inc (UNCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
UNCY|Unicycive Therapeutics Inc|Price:5.185|Chg%:-0.215 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive The - The National Law Review
TradingKey - TradingKey
Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bronstein, Gewirtz & Grossman, LLC (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Unicycive Therapeutics Inc (UNCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Unicycive Therapeutics Inc (UNCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval - Stocktwits
Unicycive Therapeutics Inc (UNCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeut - The National Law Review
2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-07-15 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group - The Globe and Mail
UNCY: Unicycive Therapeutics Investors with Losses Should - GlobeNewswire
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation - GlobeNewswire Inc.
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc. - GlobeNewswire
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
Millennium-affiliated holders disclose 271,456 shares in Unicycive Therapeutics (UNCY) - Stock Titan
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal
Weekly Recap: FDA acceptance, June 29 date and Brokers keep Buy ratings - TradingView
Law firm probes Unicycive Therapeutics over pos... - Pluang
Price to book forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
Price to earnings forward of Unicycive Therapeutics, Inc. – NASDAQ:UNCY - TradingView
UNCYUnicycive Therapeutics Inc Short Interest - Finviz
Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position - The Globe and Mail
Bragar Eagel & Squire, P.C. is Investigating Unicycive - GlobeNewswire
Unicycive Therapeutics, Inc. Files Form 8-K for Key Event on July 2, 2026 – Company Details, NASDAQ Ticker, and Emerging Growth Status – Minichart - Minichart
Unicycive Therapeutics reports $61.4M cash balance as of June 30, 2026 - TradingView
Unicycive Therapeutics (UNCY) discloses $61.4M cash balance in preliminary Q2 2026 update - Stock Titan
$Unicycive Therapeutics (UNCY.US)$ FDA reject on the previous reject. See below. - Moomoo
UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton - marketscreener.com
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Form 144 Unicycive Therapeutics For: 1 July By Investing.com - Investing.com Nigeria
Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies - Yahoo Finance
Unicycive Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Unicycive plummets following second CRL for OLC for hyperphosphatemia - MSN
UNCY Maintained by Benchmark -- Price Target Lowered to $13.00 - GuruFocus
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):